nach oben

Erschienen in:

01.06.2008 | ORIGINAL ARTICLE

Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis

verfasst von: Norimasa Miura, Hiroko Kabashima, Mika Shimizu, Reina Sato, Tomoe Tsukamoto, Tomomi Harada, Shunsaku Takahashi, Ryujin Endo, Nobuaki Nakayama, Yasuhiro Takikawa, Satoshi Mochida, Kazuyuki Suzuki, Junichi Hasegawa, Goshi Shiota

Erschienen in: Hepatology International | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Purpose

We previously reported that measuring serum telomerase reverse transcriptase (hTERT) mRNA with a quantitative, one-step, real-time RT-PCR was superior to conventional tumor markers for hepatocellular carcinoma and lung cancer. Here, we examined serum regeneration-related mRNA detection as a biomarker for fulminant hepatitis (FH).

Methods

In 53 patients, including 17 patients with acute hepatitis (AH), seven with severe hepatitis (SH), four with late-onset hepatic failure (LOHF), and 25 with FH, we measured serum mRNA levels of hTERT, hepatocyte growth factor (HGF), hepatocyte growth factor receptor (c-met), epidermal growth factor receptor (EGFR), and transforming growth factor-alpha (TGF-α). We examined the sensitivity and specificity of the technique in FH diagnosis as well as its clinical and prognostic significance compared with other clinical and prognostic tests.

Results

Serum copy number of TGF-α mRNA in FH on admission was significantly smaller than in AH and SH. In FH, TGF-α mRNA level was 10⁶-fold higher in survivors than in patients who died or received liver transplants (P = 0.034), although these patients were not discriminated by other clinical parameters. The sensitivity/specificity for prognosis in FH was 74.3/65.5% for TGF-α mRNA. Of four prognostic scoring systems, only logit-λ was useful for prognosis assessment.

Conclusions

TGF-α mRNA is an early predictor of FH outcome and a sensitive biomarker of lower regenerative liver capacity. This assay could help facilitate early therapy choice, such as liver transplantation.

Sato S, Suzuki K, Takikawa Y, Endo R, Omata M, Japanese National Study Group of Fulminant Hepatitis. Clinical epidemiology of fulminant hepatitis in Japan before the substantial introduction of liver transplantation: an analysis of 1309 cases in a 15-year national survey. Hepatol Res 2004;30:155–61.PubMedCrossRef

Fujiwara K: Japanese national survey of FH in 2000. In: Omata M, editor. The 2001 annual report of research group of intractable hepatitis. Tokyo: The Ministry of Health and Welfare of Japan; 2002. p. 87–96.

Trey C, Lipworth L, Dabidson CS. Parameters influencing survival in the first 318 patients reported to the fulminant hepatic failure surveillance study. Gastroenterology 1970;73:306.

Horney JT, Galambos JT. The liver during and after fulminant hepatitis. Gastroenterology 1977;73:639–45.PubMed

Michalopoulos GK. Liver regeneration: molecular mechanisms of growth control. FASEB J 1990;4:176–87.PubMed

Zarnegar R, DeFrances MC, Michalopoulos GK. Hepatocyte growth factor; its role in hepatic growth, pathology. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz. DA, editors. Liver: biology and pathology. New York: Raven Press; 1994. p. 1047–57.

Fausto N. Hepatic regeneration. In: Zakim D, Boyer TD, editors. Hepatology. Philadelphia: WB Saunders; 1996. p. 32–57.

Jhappan C, Stahle C, Harkins RN, Fausto N, Smith GH, Merlino GT. TGF alpha overexpression in transgenic mice induces liver neoplasia and abnormal development of the mammary gland and pancreas. Cell 1990;61:1137–46.PubMedCrossRef

Shiota G, Wang TC, Nakamura T, Schmidt EV. Hepatocyte growth factor in transgenic mice: effects on hepatocyte growth, liver regeneration and gene expression. Hepatology 1994;19:962–72.PubMed

10.

Fujiwara K, Nagoshi S, Ohno A, Hirata K, Ohta Y, Mochida S, et al. Stimulation of liver growth by exogenous human hepatocyte growth factor in normal and partially hepatectomized rats. Hepatology 1993;18:1443–9.PubMedCrossRef

11.

Ishiki Y, Ohnishi H, Muto Y, Matsumoto K, Nakamura T. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. Hepatology 1992;16:1227–35.PubMed

12.

Webber EM, Godowski PJ, Fausto N. In vivo response of hepatocytes to growth factors requires an initial priming stimulus. Hepatology 1994;19:489–97.PubMed

13.

Liu ML, Mars WM, Zarnegar R, Michalopoulos GK. Collagenase pretreatment and the mitogenic effects of hepatocyte growth factor and transforming growth factor-alpha in adult rat liver. Hepatology 1994;19:1521–7.PubMed

14.

Todaro GJ, Fryling C, De Larco JE. Transforming growth factors produced by certain human tumor cells: polypeptides that interact with epidermal growth factor receptors. Proc Natl Acad Sci USA 1980;77:5258–62.PubMedCrossRef

15.

Massague J. Epidermal growth factor-like transforming growth factor. II. Interaction with epidermal growth factor receptors in human placenta membranes and A431 cells. J Biol Chem 1983;258:13614–20.PubMed

16.

Derynck R. Transforming growth factor alpha. Cell 1988;54:593–5.PubMedCrossRef

17.

Johnson AC, Garfield SH, Merlino GT, Pastan I. Expression of epidermal growth factor receptor proto-oncogene mRNA in regenerating rat liver. Biochem Biophys Res Commun 1988;150:412–8.PubMedCrossRef

18.

Mead JE, Fausto N. Transforming growth factor alpha may be a physiological regulator of liver regeneration by means of an autocrine mechanism. Proc Natl Acad Sci USA 1989;86:1558–62.PubMedCrossRef

19.

Fisher DA, Lakshmanan J. Metabolism and effects of epidermal growth factor and related growth factors in mammals. Endocr Rev 1990;11:418–42.PubMed

20.

Fausto N, Webber EM. Liver regeneration. In: Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter DA, Shafritz DA, editors. The liver: biology, pathology. New York: Raven Press; 1994. p. 1059–84.

21.

Chen XQ, Bonnefoi H, Pelte MF, Lyautey J, Lederrey C, Movarekhi S, et al. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin Cancer Res 2000;6:3823–6.PubMed

22.

Kopreski MS, Benko FA, Kwak LW, Gocke CD. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin Cancer Res 1999;5:1961–5.PubMed

23.

Pelosi G, Schianchi E, Dell’Orto P, Veronesi G, Spaggiari L, Pasini F, et al. Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients. Virchows Arch 2005;29:1–9.

24.

Miura N, Shiota G, Nakagawa T, Sano A, Marumoto A, Kishimoto Y, et al. Sensitive detection of hTERT mRNA in the serum of patients with hepatocellular carcinoma. Oncology 2003;64:430–4.PubMedCrossRef

25.

Miura N, Maeda Y, Kanbe T, Yazama H, Takeda Y, Sato R, et al. Serum human Telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma. Clin Cancer Res 2005;11:3205–9.PubMedCrossRef

26.

Miura N, Nakamura H, Sato R, Tsukamoto T, Harada T, Takahashi S, et al. Clinical usefulness of serum telomerase reverse transcriptase (hTERT) mRNA and epidermal growth factor receptor (EGFR) mRNA as a novel tumor marker for lung cancer. Cancer Sci 2006;97:1366–73.PubMedCrossRef

27.

Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T. Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology 1995;21:106–12.PubMed

28.

Trey C, Davidson CS. The management of fulminant hepatic failure. In: Popper H, Schaffner F, editors. Progress in liver diseases, vol. III. Philadelphia: Grune, Stratton; 1970. p. 282–298.

29.

Gimson AES, O’Grandy J, Ede RJ, Portmann B, Williams R. Late onset hepatic failure :clinical, serological and histological fatures. Hepatology 1986;6:288–94.PubMedCrossRef

30.

Wege H, Chui MS, Le HT, Strom SC, Zern MA. In vitro expansion of human hepatocytes is restricted by telomere-dependent replicative aging. Cell Transplant 2003;12:897–906.PubMed

31.

Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464.PubMedCrossRef

32.

O’Grady JG, Alexander GJM, Hayllar KM, Williams R. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 1989;97:439–45.PubMed

33.

Takikawa Y, Endo R, Suzuki K, Fujiwara K, Omata M, The Fulminant Hepatitis Study Group of Japan. Prediction of hepatic encephalopathy development in patients with severe acute hepatitis. Dig Dis Sci 2006;51:359–64.PubMedCrossRef

34.

Sugihara J, Naito T, Ishiki Y, Murakami N, Naiki T, Koshino Y, et al. A multicenter study on the prognosis and indications of liver transplantation for fulminant hepatitis in Japan. Details of decision of the guideline for liver transplantation in Japanese acute hepatic failure study group. Acta Hepatol Jap 2001;42:543–57.

35.

Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266:2011–5.PubMedCrossRef

36.

Tatsuma T, Goto S, Kitano S, Lin YC, Lee CM, Chen CL. Telomerase activity in peripheral blood for diagnosis of hepatoma. J Gastroenterol Hepatol 2000;15:1064–70.PubMedCrossRef

37.

Ng EK, Tsui NB, Lam NY, Chiu RW, Yu SC, Wong SC, et al. Presence of filterable and non filterable mRNA in the plasma of cancer patients and healthy individuals. Clin Chem 2002;48:1212–7.PubMed

38.

Tsui NB, Ng EK, Lo YM. Stability of endogeneous and added RNA in blood specimens, serum, and plasma. Clin Chem 2002;48:1647–53.PubMed

39.

Tomiya T, Fujiwara K. Liver regeneration in fulminant hepatitis as evaluated by serum transforming growth factor alpha levels. Hepatology 1996;23:253–7.PubMed

40.

Kanda D, Takagi H, Toyoda M, Horiguchi N, Nakajima H, Otsuka T, et al. Transforming growth factor alpha protects against Fas-mediated liver apoptosis in mice. FEBS Lett 2002;22:11–5.CrossRef

41.

Nass SJ, Li M, Amundadottir LT, Furth PA, Dickson RB. Role for Bcl-xL in the regulation of apoptosis by EGF and TGF beta 1 in c-myc overexpressing mammary epithelial cells. Biochem Biophys Res Commun 1996;3:248–56.CrossRef

42.

Amundadottir LT, Nass SJ, Berchem GJ, Johnson MD, Dickson RB. Cooperation of TGF alpha and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene 1996;15:757–65.

43.

Reinartz J, Bechtel MJ, Kramer MD. Tumor necrosis factor-alpha-induced apoptosis in a human keratinocyte cell line (HaCaT) is counteracted by transforming growth factor-alpha. Exp Cell Res 1996;1:334–40.CrossRef

44.

Christensen JG, Goldsworthy TL, Cattley RC. Dysregulation of apoptosis by c-myc in transgenic hepatocytes and effects of growth factors and nongenotoxic carcinogens. Mol Carcinog 1999;25:273–84.PubMedCrossRef

45.

Musallam L, Ethier C, Haddad PS, Bilodeau M. Role of EGF receptor tyrosine kinase activity in antiapoptotic effect of EGF on mouse hepatocytes. Am J Physiol Gastrointest Liver Physiol 2001;280:G1360–9.PubMed

46.

Blanc P, Etienne H, Daujat M, Fabre I, Zindy F, Domergue J, et al. Mitotic responsiveness of cultured adult human hepatocytes to epidermal growth factor, transforming growth factor alpha, and human serum. Gastroenterology 1992;102:1340–50.PubMed

47.

Shiota G, Okano J, Kawasaki H, Kawamoto T, Nakamura T. Serum hepatocyte growth factor levels in liver diseases: clinical implications. Hepatology 1995;21:106–12.PubMedCrossRef

48.

Tsubouchi H, Kawakami S, Hirono S, Miyazaki H, Kimoto M, Arima T, et al. Prediction of outcome in fulminant hepatic failure by serum human hepatocyte growth factor. Lancet 1992;1:307.CrossRef

49.

Tomiya T, Nagoshi S, Fujiwara K. Significance of serum human hepatocyte growth factor levels in patients with hepatic failure. Hepatology 1992;15:1–4.PubMedCrossRef

50.

Kusaka K, Imamura H, Tomiya T, Makuuchi M. Factors affecting liver regeneration after right portal vein embolization. Hepatogastroenterology 2004;51:532–5.PubMed

51.

Ostapowicz G, McCashland TM, Shakil O, the ALF Study Group. An increase in alpha-fetoprotein predicts survival in acute liver failure. Hepatology 1999;72:479–82.

52.

Bernal W, Donaldson N, Wyncoll D, Wendon J. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 2002;359:558–63.PubMedCrossRef

53.

Furuta K, Kakita A, Takahashi T, Tomiya T, Fujiwara K. Experimental study on liver regeneration after simultaneous partial hepatectomy and pancreatectomy. Hepatology Res 2000;17:223–36.CrossRef

54.

Efimova EA, Glanemann AK, Nussler G, Schumacher U, Settmacher S, Jonas N, et al. Changes in serum levels of growth factors in healthy individuals after living related liver donation. Transplant Proc 2005;37:1074–5.PubMedCrossRef

Titel: Clinical impact of serum transforming growth factor-alpha mRNA as a predictive biomarker for the prognosis of fulminant hepatitis
verfasst von: Norimasa Miura
Hiroko Kabashima
Mika Shimizu
Reina Sato
Tomoe Tsukamoto
Tomomi Harada
Shunsaku Takahashi
Ryujin Endo
Nobuaki Nakayama
Yasuhiro Takikawa
Satoshi Mochida
Kazuyuki Suzuki
Junichi Hasegawa
Goshi Shiota
Publikationsdatum: 01.06.2008
Verlag: Springer-Verlag
Erschienen in: Hepatology International / Ausgabe 2/2008
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-008-9053-6

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Strenge Blutdruckeinstellung lohnt auch im Alter noch

30.04.2024 Arterielle Hypertonie Nachrichten

Ältere Frauen, die von chronischen Erkrankungen weitgehend verschont sind, haben offenbar die besten Chancen, ihren 90. Geburtstag zu erleben, wenn ihr systolischer Blutdruck < 130 mmHg liegt. Das scheint selbst für 80-Jährige noch zu gelten.

Frauen bekommen seltener eine intensive Statintherapie

30.04.2024 Statine Nachrichten

Frauen in den Niederlanden erhalten bei vergleichbarem kardiovaskulärem Risiko seltener eine intensive Statintherapie als Männer. Ihre LDL-Zielwerte erreichen sie aber fast ähnlich oft.

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Nonalcoholic fatty liver disease in a district general hospital: clinical presentation and risk factors

Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM)-resistant hepatitis B virus (HBV)

Reviews for APASL guidelines: immunomodulator therapy of chronic hepatitis B

A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH)

Chronic HBV infection with persistently normal ALT b. not to treat